<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoyle, Brian</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Salsali, Afshin</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Empagliflozin Reduces BP in Hypertensive Type 2 Diabetics</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-15</style></pages><abstract><style  face="normal" font="default" size="100%">Prior 24-week Phase 3 clinical trials (randomized, double-blind) established the efficacy of empagliflozin (10 and 25 mg) in reducing systolic BP compared with placebo among patients with type 2 diabetes. This article presented findings of the 12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus [EMPA-REG BP; NCT01370005], a placebo-controlled Phase 3 trial (randomized, double-blind).</style></abstract><number><style face="normal" font="default" size="100%">20</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>